It’s another study where TMZ shows a better mOS outcome than in...

It’s another study where TMZ shows a better mOS outcome than in their pivotal study.
A replication of the final Phase II data in GBM AGILE would cut it close if the TMZ arm performed anywhere near the value reported in this or more recent studies.
Personally I am hoping that final GBM AGILE is closer to the late interim results for paxalisib in terms of mOS. Given the much larger sample size a few outliers wouldn’t impact the median results as much as they did in the Phase II study.